Lesinurad

Urate Transporter 1 Inhibitor — MUSCULO-SKELETAL SYSTEM

Key facts

Lesinurad is an ofm drug in the Urate Transporter 1 Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2015. Its mechanism of action is classified as Cytochrome P450 3A Inducers and Urate Transporter 1 Inhibitors. DrugCentral lists 2 molecular targets, including SLC22A11 and SLC22A12. Recorded indications include Hyperuricemia.

• Approval status: ofm (first approved 2015 by the FDA).
• Drug class: Urate Transporter 1 Inhibitor.
• Mechanism of action: Cytochrome P450 3A Inducers; Urate Transporter 1 Inhibitors.
• Molecular targets: SLC22A11 and SLC22A12 (2 listed in DrugCentral).
• Indications: Hyperuricemia.
• ATC code: M04AB05 (Preparations increasing uric acid excretion).
• Molecular formula: C17H14BrN3O2S; molecular weight 404.28 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Hyperuricemia

Mechanism & targets

• Mechanism of action (MoA): Cytochrome P450 3A Inducers; Urate Transporter 1 Inhibitors
• Established pharmacologic class: Urate Transporter 1 Inhibitor

Molecular targets (2)

Target	Gene	Action	Activity
Solute carrier family 22 member 11	SLC22A11	inhibitor	IC50 5.43
Solute carrier family 22 member 12	SLC22A12	inhibitor	IC50 5.14

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2016-02-18	EMA	—	AstraZeneca AB
2015-12-22	FDA	—	ARDEA BIOSCIENCES INC

ATC classification

ATC code	Therapeutic hierarchy
M04AB05	MUSCULO-SKELETAL SYSTEM › ANTIGOUT PREPARATIONS › ANTIGOUT PREPARATIONS › Preparations increasing uric acid excretion

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: CYP2C9 · Actionable PGx
• FDA label: CYP2C9 · Actionable PGx
• Swissmedic label: CYP2C9 · Informative PGx

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Lesinurad is on its molecule page.

• Molecular formula: C₁₇H₁₄BrN₃O₂S
• Molecular weight: 404.28 g/mol
• CAS number: 878672-00-5
• InChIKey: FGQFOYHRJSUHMR-UHFFFAOYSA-N
• PubChem CID: 53465279

OC(=O)CSC1=NN=C(Br)N1C1=C2C=CC=CC2=C(C=C1)C1CC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Lesinurad used for?

DrugCentral lists the following indications for Lesinurad: Hyperuricemia.

How does Lesinurad work?

Lesinurad is classified as Cytochrome P450 3A Inducers and Urate Transporter 1 Inhibitors; its molecular targets in DrugCentral include SLC22A11 (inhibitor) and SLC22A12 (inhibitor).

When was Lesinurad first approved?

Lesinurad was first approved by the FDA in 2015.

What drug class does Lesinurad belong to?

Lesinurad is in the Urate Transporter 1 Inhibitor class.

What is the chemical formula of Lesinurad?

Lesinurad has the molecular formula C17H14BrN3O2S and a molecular weight of 404.28 g/mol.

Sources

• DrugCentral drug card 5075 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2105716 — compound record and bioactivity
• PubChem CID 53465279 — chemical identifiers
• DrugBank DB11560 — drug record
• FDA UNII 09ERP08I3W — substance identity
• DailyMed: FDA labels for Lesinurad — current prescribing information (label search)
• UniProt Q9NSA0 (SLC22A11) — target protein
• UniProt Q96S37 (SLC22A12) — target protein
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.